View
219
Download
1
Category
Tags:
Preview:
Citation preview
Things we knew, things we did… Things we have learnt, things we should do
Alain Wajman M.D., Cardiologist Prat Hosp. Clin. Spe
Rothschild Hospital APHP, Paris
Post MI Heart Failure with Left Ventricular Dysfunction Management
and Aldosterone Blockade
2
Heart Failure
Disease with the highest prevalence in the next decade
50% of elderly (age 70 - 80) 50%: ischaemic heart disease (post MI and
LVD) High costs for public health Prognosis: poor but improving
One-year mortality • 5% NYHA class I• 25-30% NYHA class IV
3 Jessup M and Brozena S. N Engl J Med 2003;348:2007-2018
Ventricular REMODELINGAfter Acute Infarction
4
Neurohormonal changes: VC > VD
Vasoconstriction:1.Noradrenaline2.Renin Angiotensine System3.Endothelin4.Arginin Vasopressin5.Cytokines
Vasoconstriction:1.Noradrenaline2.Renin Angiotensine System3.Endothelin4.Arginin Vasopressin5.Cytokines
Vasodilation /Antiproliferative substances:1.Natriuretic peptides2.Bradykinines 3.NO4.Adrenomedulline
Vasodilation /Antiproliferative substances:1.Natriuretic peptides2.Bradykinines 3.NO4.Adrenomedulline
5 Jessup M and Brozena S. N Engl J Med 2003;348:2007-2018
Targets for Heart Failure Treatment
•Diuretics•ACE I, AIIRAs•Beta-blockers•Anti-aldosterone
AntiarrhytmicsCCBsAIIRAsAntiplateletsAnticoagulantsStatins?
6Jessup M and Brozena S. N Engl J Med 2003;348:2007-2018
Severity of Systolic Heart Failure And Therapeutic Options
7
Diuretics in Post MI HF with LVD
• Always mandatory, ++++ if congestion • Natriuretics • Furosemide: 40-60 mg IV, 40 to 250
mg/d• Renal vasodilation• Hyponatremia• Hypokalemia • Alkalosis • Hyperuricemia • Hypertriglyceridemia
8
Beta-blockers in Post MI HF with LVD
• If EF < 35 % to 40 % • Mandatory, start late, 4 to 6 weeks
after acute phase ….• In combination with ACE I • Carvedilol• Bisoprolol• Metoprolol • Nebivolol
• Start Late, Low, and go Slow • Control: HR, BP, Diuresis, Body
weight
9
ACE I or ARBs (AIIRAs) “sartans”in HF with low ejection fraction
Candesartan, CHARM trial:• 7000 patients with heart failure already
receiving an ACE I or intolerant to an ACE I and low EF < 40%
• Significant mortality and rehospitalization reduction
• No benefit if EF > 40%• Candesartan: 4.8 mg then 16 to 32 mg/d
10Weber K. N Engl J Med 2001;345:1689-1697
The Renin-Angiotensin-Aldosterone System
11 Dluhy R and Williams G. N Engl J Med 2004;351:8-10
Physiologic and Pathophysiologic Effects of Aldosterone on the Kidney and Heart
in Relation to Dietary Salt Levels
12Ernst M and Moser M. N Engl J Med 2009;361:2153-2164
Sites of Diuretic Action in the Nephron
13
Weber K. N Engl J Med 2001;345:1689-1697
Extraadrenal Production of Aldosterone by Endothelial and Vascular Smooth-Muscle Cells in an Intramyocardial Coronary Artery
14
Weber K. N Engl J Med 2001;345:1689-1697
Coronary Vascular Remodelling
in Hyperaldosteronism in Rats
15
EPHESUS: Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study
Objective
To evaluate the effects of eplerenone (a selective aldosterone blocker):
• on morbidity and mortality
• in patients with acute myocardial infarction (MI) complicated by left ventricular dysfunction and heart failureReference
Pitt B, Remme W, Zannad F et al. for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309–21.
16
EPHESUS: Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study
- TRIAL DESIGN -
DesignMulticentre, multinational, randomized, double-blind, placebo-controlled
Patients6632 patients 3–14 days after acute MI, who had left ventricular ejection fraction <40% and were receiving optimal treatment, which could include ACE inhibitors, angiotensin receptor blockers, diuretics (other than K+-sparing diuretics) and beta-blockers
Follow-up and primary endpointsPrimary endpoints: all-cause mortality; death from cardiovascular cause or first hospitalization for cardiovascular event. Mean 16 months follow-up.
TreatmentPlacebo or eplerenone titrated to target dose 50 mg daily
17
EPHESUS: Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study
Age (years)a
Male (%)
HistoryLeft ventricular ejection fraction (%)a
Days from MI to randomizationa
Symptoms of heart failure
MedicationsACE inhibitor or angiotensin-receptor blockerBeta-blockersDiureticsAspirinStatins
Baseline characteristics
64
70
337.390
8775618947
Placebo(n=3313)
64
72
337.390
8675608847
Eplerenone(n=3319)
Pitt et al. N Engl J Med 2003;348:1309–21.a Mean
18
EPHESUS: Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study
- RESULTS -
• Both primary endpoints significantly reduced in eplerenone group compared with placebo:
—all-cause mortality: 14.4 vs. 16.7% (RR 0.85, P=0.008)—death or hospitalization due to cardiovascular event: 26.7 vs.
30.0% (RR 0.87, P=0.002)• Significantly fewer hospitalizations for cardiovascular events in
eplerenone group, attributable to significant reduction in hospitalizations for heart failure
• Incidence of gynecomastia in the two groups was similar.• Incidence of serious hyperkalemia significantly higher in
eplerenone group; serious hypokalemia significantly lower• Drug well tolerated as defined by withdrawal rate from trial: only
marginally higher with eplerenone
19
EPHESUS: Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study
- RESULTS, continued -
Months after randomization
Cumulativeincidence
(%)
00
6 12 18 24 30 36
40
30
20
10
All-cause mortality
Pitt et al. N Engl J Med 2003;348:1309–21.
Placebo
Eplerenone
RR=0.85(95% CI=0.75–0.96)P=0.008
20
EPHESUS: Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study
- RESULTS, continued -
Primary and selected secondary endpoints
Pitt et al. N Engl J Med 2003;348:1309–21.
P
Primary endpointsAll-cause mortalityCardiovascular death or
hospitalization forcardiovascular events
Secondary endpoints (No.)Hospitalization for cardiovascular events
Acute MIHeart failureStrokeVentricular arrhythmia
0.85 (0.75–0.96)0.87 (0.79–0.95)
0.0080.002
0.03
0.960.0020.110.69
478 (14.4)885 (26.7)
No. (%)
Eplerenone(n=3319)
554 (16.7)993 (30.0)
1004
2696185463
876
2684777358
0.87
0.990.771.350.92
No. (%)
Placebo(n=3313)
Relative risk(95% CI)or ratio
21
Pitt B et al. N Engl J Med 2003;348:1309-1321
EPHESUS main results
Deaths from any cause
Deaths from CV cause or hospitalizations
Sudden death from cardiac causes
-15%
-21%
-13%
22
EPHESUS: Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study
- RESULTS, continued -
P
Gynecomastia
Serious hyperkalemia(serum potassium >6 mmol/L)
Serious hypokalemia(serum potassium <3.5 mmol/L)
Adverse events
12
180
273
No.
(0.5)
(5.5)
(8.4)
0.70
0.002
<0.001
(%)
Eplerenone(n=3307)
14
126
424
No.
(0.6)
(3.9)
(13.1)
(%)
Placebo(n=3301)
Pitt et al. N Engl J Med 2003;348:1309–21.
23
EPHESUS: Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study
- SUMMARY -
In patients with acute myocardial infarction (MI) complicated by left ventricular dysfunction and heart failure, eplerenone:
• Reduced all-cause mortality, and reduced death or hospitalization due to cardiovascular events
• Had no effect on the incidence of gynecomastia
• Increased the incidence of serious hyperkalemia but decreased serious hypokalemia
NEJM 2003
24
Post MI Heart failure with LVD Take-home messages
1. Clinical examination 2. X-ray3. Cardiac ultrasound (ejection fraction)4. BNP or NT-Pro BNP5. Body weight 6. Blood pressure control7. Repeat ionograms ( Na, K, …) 8. Kidney function 9. Use drugs at the “right dosages”10.Eplerenone at top of standard treatment
(EPHESUS)
Things we knew, things we did… Things we have learnt, things we should do
Questions? ~ Answers!
International Congress of Medicine for Everyday Practice
26
NT pro-BNP and heart failure
<300
HF ProbabliltyLOW
1800900450
>75 yrs50-75yrs<50 yrs
ng/l
HF and AGE
G.Meune 2008
27
Weber K. N Engl J Med 2001;345:1689-1697
Compensated and Decompensated Heart Failure, as Indicated by the Presence or Absence of Urinary Sodium Retention, Together with Symptoms and Signs of Expanded Intravascular and
Extravascular Volume
Recommended